Last reviewed · How we verify

Any other OC

Bayer · Phase 2 active Small molecule ✓ Verified Jun 2026

Any other OC is a Contraceptives Small molecule drug developed by Bayer. It is currently in Phase 2 development for Contraception.

Any other OC works by preventing ovulation.

The study "Identification of Cellular Biomarkers of Rare Eye Diseases in Adults" is investigating rare eye diseases in adults, with interventions including ophthalmological visits and blood sample collection. This study is being conducted by the Institut National de la Santé Et de la Recherche Médicale in France.

Likelihood of approval
18.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • Big-pharma sponsor +3.0pp
    Bayer is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034 —
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameAny other OC
SponsorBayer
Drug classContraceptives
ModalitySmall molecule
Therapeutic areaWomen's Health
PhasePhase 2

Mechanism of action

Any other OC contains a combination of estrogen and progestin that suppresses the release of gonadotropin-releasing hormone, which in turn prevents the release of luteinizing hormone and follicle-stimulating hormone, thereby preventing ovulation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Any other OC

What is Any other OC?

Any other OC is a Contraceptives drug developed by Bayer, indicated for Contraception.

How does Any other OC work?

Any other OC works by preventing ovulation.

What is Any other OC used for?

Any other OC is indicated for Contraception.

Who makes Any other OC?

Any other OC is developed by Bayer (see full Bayer pipeline at /company/bayer).

What drug class is Any other OC in?

Any other OC belongs to the Contraceptives class. See all Contraceptives drugs at /class/contraceptives.

What development phase is Any other OC in?

Any other OC is in Phase 2.

What are the side effects of Any other OC?

Common side effects of Any other OC include Nausea, Breast tenderness, Headache, Mood changes, Vaginal bleeding irregularities.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing